Table 2.
Pathomorphological (MEST) and clinical data of IgAN patient subgroups with specific clinical syndromes
| Presenting clinical syndrome (n, %) | At the time of biopsy | At the end of follow-up | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| M (N, %) | E (N, %) | S (N, %) | T (N, %) | eGFR (ml/min) | U-Prot (g/day) | MAP (mmHg) | eGFR (ml/min) | U-Prot (g/day) | MAP (mmHg) | |
| Macroscopic haematuria (3, 4%, all Untreated) | 2; 67 | 0 | 2; 67 | 0 | 98.9 ± 25.6 | 0.4 ± 0.3 | 84.3 ± 10.1 | 109.1 ± 16.3 | 0.4 ± 0.3 | 91.7 ± 10.9 |
| Asymptomatic microhematuria (35, 48%) | 20; 57 | 7; 20 | 12; 34 | 2; 6 | 105.3 ± 30.7 | 0.1 ± 0.1 | 90.6 ± 8.4 | 95.1 ± 22.5 | 0.3 ± 0.8 | 92.2 ± 6.2 |
| • Drug-treated (13, 37%) | 9; 69 | 0 | 5; 38 | 2; 15 | 102.8 ± 36.9 | 0.1 ± 0.1 | 92.4 ± 10.5 | 88.8 ± 23.4 | 0.5 ± 1.1 | 92.8 ± 6.6 |
| • Untreated (22, 63% | 11; 50 | 7; 32 | 7; 32 | 0 | 106.7 ± 27.1 | 0.1 ± 0.1 | 89.7 ± 7.2 | 98.8 ± 21.6 | 0.2 ± 0.4 | 91.7 ± 6.0 |
| Asymptomatic microhematuria and proteinuria (28, 39%) | 24; 86 | 11; 39 | 18; 64 | 3; 11 | 89.8 ± 20.8 | 0.9 ± 0.6 | 101.1 ± 11.2 | 82.1 ± 29.9 | 1.0 ± 1.4 | 97.4 ± 9.9 |
| • Drug-treated (20, 71%) | 20; 100 | 9; 45 | 14; 50 | 2; 7 | 83.0 ± 18.9 | 1.0 ± 0.5 | 102.6 ± 12.5 | 75.1 ± 27.9 | 1.0 ± 1.5 | 97.1 ± 10.6 |
| • Untreated (8, 29% | 4; 50 | 2; 25 | 4; 50 | 1; 13 | 106.8 ± 15.3 | 0.8 ± 0.6 | 97.3 ± 6.1 | 99.7 ± 28.8 | 1.1 ± 1.2 | 98.1 ± 8.5 |
| NS (5, 7%, all drug-treated) | 5; 100 | 4; 80 | 5; 100 | 1; 20 | 73.9 ± 42.5 | 5.9 ± 2.6 | 100.3 ± 10.6 | 67.0 ± 28.3 | 1.1 ± 0.7 | 97.5 ± 11.4 |
NS nephrotic syndrome, eGFR estimated glomerular filtration rate, MAP mean arterial pressure, U-Prot urinary protein excretion, M mesangial hypercellularity, E endocapillary hypercellularity, S segmental glomerulosclerosis, T tubular atrophy/interstitial fibrosis